Neurocrine Biosciences Inc. said Friday that the U.S. Food and Drug Administration has approved Ingrezza for treatment of an involuntary movement disorder...
Neurocrine Biosciences Inc.
said Friday that the U.S. Food and Drug Administration has approved Ingrezza for treatment of an involuntary movement disorder linked with Huntington’s disease, prompting analysts at Oppenheimer to boost their price target on the shares. “Ingrezza could become a pipeline-in-a-product,” based on additional indications beyond the movement disorder, called chorea, the Oppenheimer analysts wrote in a note Sunday, raising their price target on the stock to $154, from $150 previously.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
‘Oppenheimer’ Soaring Past $700M Global Box Office Today, Will Overtake Christopher Nolan’s ‘Interstellar’ On SundayUPDATE, SATURDAY August 19: Christopher Nolan and Universal’s Oppenheimer is on its way to yet another milestone, poised to cross $700M global through today. After five frames, the epic is expected…
Read more »
‘Oppenheimer’ Poised to Overtake ‘Interstellar’s Total Haul at the Global Box OfficeThen, it'll set its sights on passing 'Inception.'
Read more »
Did Oppenheimer Regret Creating The Atomic Bomb?Oppenheimer was full of anxiety about the future.
Read more »
Christopher Nolan’s ‘Oppenheimer’ Surpasses $700 Million GloballyChristopher Nolan’s “Oppenheimer” has surpassed $700 million at the global box office, becoming the fourth-highest grossing movie of the year. After five weeks of release, the R-r…
Read more »
'Oppenheimer' Becomes 4th Highest-Grossing Movie of 2023'Oppie' exploded past $700 million this weekend, passing 'Fast X' and 'Across the Spider-Verse'.
Read more »